The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | V | Various | |
| 2 | V03 | All other therapeutic products | |
| 3 | V03A | All other therapeutic products | |
| 4 | V03AE | Drugs for treatment of hyperkalemia and hyperphosphatemia | |
| 5 | V03AE02 | Sevelamer |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| ORAL - Oral | 6.4 g |
| Active Ingredient | Description | |
|---|---|---|
| Sevelamer |
Sevelamer is a non-absorbed phosphate binding crosslinked polymer, free of metal and calcium. Sevelamer contains multiple amines separated by one carbon from the polymer backbone which become protonated in the stomach. These protonated amines bind negatively charged ions such as dietary phosphate in the intestine. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| RENVELA Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
| RENVELA Powder for oral suspension | European Medicines Agency (EU) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
